8.1K
Articles
237.5K
Citations
3.1
avg. Impact Factor
199
h-index

Most Cited Articles of Division of Hematology in 2013

TitleJournalYearCitations
Mutations and prognosis in primary myelofibrosisLeukemia2013520
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Mayo Clinic Proceedings2013341
Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experienceGut2013276
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myelomaCancer Cell2013242
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupLeukemia2013222
How I treat monoclonal gammopathy of renal significance (MGRS)Blood2013197
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemiaLeukemia2013187
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myelomaLeukemia and Lymphoma2013177
Cold agglutinin diseaseBlood2013168
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia2013168
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus projectBlood2013159
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myelomaLeukemia2013158
CarfilzomibBlood2013152
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaLeukemia2013152
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomesLeukemia2013151
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patientsBritish Journal of Haematology2013151
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemiaNature Genetics2013147
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosisBone Marrow Transplantation2013124
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemiaCancer2013121
Implantable cardioverter defibrillators in patients with cardiac amyloidosisJournal of Cardiovascular Electrophysiology2013118
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276Leukemia2013116
Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern eraAmerican Journal of Transplantation2013116
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myelomaLeukemia2013113
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevanceAmerican Journal of Hematology2013112
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 studyAnnals of Oncology201393